A Phase II Evaluation of AMG 102 (IND Pending, NSC 750009) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 09 Sep 2017
At a glance
- Drugs Rilotumumab (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Biomarker; Therapeutic Use
- 09 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 22 Nov 2010 Actual initiation date (Dec 2009) added as reported by ClinicalTrials.gov.
- 22 Nov 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.